

Evolution of Pharmacopoeial Standards in India: Scientific, Institutional and Regulatory Perspectives

Dr. Ashish Kumar Jaiswal¹

¹BHMS, M.D.(Hom.), MBA (HCA), Ph.D. (Hom); Joint Advisor; Ministry of Ayush, Government of India

Publication Date: 2026/10/26

Abstract: The Indian Pharmacopoeia (IP) is India's principal official compendium of drug quality standards. It plays a central role in ensuring the identity, purity, strength, and quality of pharmaceutical substances and medicinal preparations. The IP is published by the Indian Pharmacopoeia Commission (IPC) under the Ministry of Health and Family Welfare, Government of India. It provides scientifically validated specifications, analytical methods, and quality-control requirements in line with the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945. The development of the IP reflects the progress of pharmaceutical sciences, analytical techniques, regulatory systems, and institutional mechanisms for quality assurance in India. Pharmacopoeial standards offer a common scientific basis for assessing drug quality, ensuring regulatory compliance, and monitoring the quality of medicines after they reach the market. Because the IP has statutory recognition, its standards are also important for regulatory enforcement and for resolving disputes related to drug quality. This paper examines the historical evolution of the Indian Pharmacopoeia. It focuses on the IP's institutional development, scientific advancements, regulatory importance, and contribution to building a strong national framework for pharmaceutical standardisation and quality assurance.

How to Cite: Dr. Ashish Kumar Jaiswal (2026) Evolution of Pharmacopoeial Standards in India: Scientific, Institutional and Regulatory Perspectives. *International Journal of Innovative Science and Research Technology*, 11(10), 1687-1691. <https://doi.org/10.38124/ijisrt/26oct941>

I. INTRODUCTION

A pharmacopoeia is an official compendium that establishes authoritative standards for the identity, purity, strength, and quality of pharmaceutical substances and medicinal preparations. It provides monographs, analytical procedures, specifications, and general requirements that support the manufacture, testing, and regulatory assessment of medicines. The development of pharmacopoeias therefore represents an important milestone in the evolution of pharmaceutical sciences, reflecting the transition from traditional descriptions of medicinal substances and preparation methods towards scientifically defined, reproducible, and verifiable quality standards.

Historically, pharmacopoeias emerged in response to the need for uniformity in the preparation and evaluation of medicines. As pharmaceutical practice expanded and medicinal products became more complex, reliance solely on traditional knowledge, individual experience, and non-uniform preparation methods became increasingly inadequate. Official pharmacopoeias consequently evolved to provide common standards for pharmaceutical ingredients and preparations, thereby promoting consistency in drug quality, facilitating analytical evaluation, and supporting public-health protection.

In India, the evolution of pharmacopoeial standardisation has been closely associated with the development of pharmaceutical education, indigenous drug manufacturing, analytical sciences, and statutory drug regulation. The enactment of the Drugs and Cosmetics Act, 1940, and the formulation of the Drugs Rules, 1945, established an important legislative foundation for regulating drug quality in the country. Following independence, the Indian Pharmacopoeia Committee was constituted in 1948 with the publication of the Indian Pharmacopoeia as one of its principal functions.[ipc.gov](https://www.ipc.gov)+3

The publication of the first edition of the Indian Pharmacopoeia in 1955 marked a major milestone in establishing nationally recognised pharmaceutical standards. It was followed by a supplement in 1960, and subsequent editions were issued in 1966, 1985, 1996, 2007, 2010, 2014, 2018, and 2022, together with relevant supplements and addenda. These successive revisions reflect advances in pharmaceutical science, analytical methodology, regulatory expectations, and the expanding range of drugs requiring official quality standards.

A historical examination of the Indian Pharmacopoeia is therefore important for understanding not only the chronology of its editions but also the broader transformation of pharmaceutical standardisation in India. Such an

examination can elucidate the influence of scientific innovation, institutional development, and legislative change on the formulation and enforcement of drug-quality standards.

The present study aims to examine the historical evolution of the Indian Pharmacopoeia, with particular emphasis on its major developmental milestones, institutional foundations, scientific advancements, and regulatory significance. It further seeks to analyse how the IP has evolved from a national compendium of drug standards into an important component of India's contemporary pharmaceutical quality-assurance framework.

➤ *Inclusion Criteria*

Materials were included if they satisfied one or more of the following criteria:

- They described the origin, development, revision, or publication of the Indian Pharmacopoeia.
- They provided information on the Indian Pharmacopoeia Committee, the Indian Pharmacopoeia Commission, or related institutional developments.
- They discussed the relationship between the IP and Indian drug legislation, particularly the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945.
- They described scientific, analytical, or regulatory developments reflected in IP monographs, general chapters, supplements, or addenda.
- They were published in English or available in officially translated form.

➤ *Exclusion Criteria*

Materials were excluded if they:

- Did not provide verifiable information relevant to the Indian Pharmacopoeia.
- Were non-scholarly commercial advertisements, unauthenticated web content, or sources lacking institutional or editorial accountability.
- Focused exclusively on foreign pharmacopoeias without relevant reference to Indian pharmaceutical standardisation.
- Contained duplicate information already available from a more authoritative primary source.

II. HISTORICAL DEVELOPMENT OF THE INDIAN PHARMACOPOEIA

The Indian Pharmacopoeia (IP) developed from early colonial-era efforts to standardise medicinal substances into a modern, statutory compendium of pharmaceutical quality standards. Its evolution reflects India's transition from reliance on imported and traditional pharmacopoeial references to the establishment of an independent national system for drug standardisation, testing, and regulation.

➤ *Early Foundations: 1833–1947*

The documented history of the IP began in 1833, when a committee of the East India Company's Dispensary

recommended the preparation of a pharmacopoeia for use in British India. This recommendation led to the publication of the *Bengal Pharmacopoeia and General Conspectus of Medicinal Plants* in 1844, which primarily listed commonly used indigenous remedies.

During the colonial period, Indian medical and pharmaceutical practice depended largely on the British Pharmacopoeia and other foreign references. Although these sources provided useful standards, they did not always address the medicinal substances, preparations, climatic conditions, and therapeutic practices relevant to India. This limitation created a need for a nationally relevant compendium that could recognise indigenous drugs and support local pharmaceutical manufacture.

➤ *Legislative and Institutional Basis: 1940–1948*

A major foundation for modern Indian drug regulation was laid with the enactment of the Drugs and Cosmetics Act, 1940. The Act provided the legal framework for controlling the import, manufacture, distribution, and sale of drugs and cosmetics in India. The Drugs Rules, 1945, subsequently operationalised many regulatory requirements under the Act.

After independence, the Government of India constituted the Indian Pharmacopoeia Committee in 1948, with the publication of an Indian Pharmacopoeia as one of its principal functions. This marked the beginning of a systematic national effort to develop official drug standards suited to Indian requirements.

➤ *First Edition and Early Growth: 1955–1975*

The first edition of the Indian Pharmacopoeia was published in 1955. It represented a landmark in Indian pharmaceutical history because it provided India with its own official collection of drug monographs, analytical methods, and quality specifications. A supplement followed in 1960, allowing necessary additions and revisions to be introduced between full editions.

The second edition was published in 1966, followed by a supplement in 1975. These publications strengthened the IP's role in supporting quality control, pharmaceutical education, and the expanding Indian drug-manufacturing sector.

➤ *Expansion and Modernisation: 1985–2005*

The third edition of the IP was published in 1985, with addenda issued in 1989 and 1991. The fourth edition followed in 1996 and was supported by an addendum in 2000, a supplement for veterinary products in 2000, and further addenda in 2002 and 2005.

This period reflected increasing recognition that pharmacopoeial standards needed to cover not only conventional pharmaceutical preparations but also veterinary medicines and emerging therapeutic categories. The inclusion of veterinary-product standards in 2000 was particularly significant because it broadened the official scope of the IP beyond human pharmaceuticals.[ipc.gov]

➤ *Contemporary Development: 2007–2022*

The fifth edition was published in 2007, followed by an addendum in 2008. The sixth edition, released in 2010, was accompanied by a DVD format, reflecting the increasing use of digital media in pharmaceutical documentation and access to standards. An addendum followed in 2012.

The seventh edition was published in 2014, with addenda in 2015 and 2016. The eighth edition, published in 2018, superseded IP 2014 and included addenda in 2019 and 2021. The IPC noted that monographs from earlier editions

not included in IP 2018 remained official as provided under the Second Schedule of the Drugs and Cosmetics Act, 1940.

The ninth and current edition, IP 2022, was released on 1 December 2022 and published in four volumes. It continues the practice of periodic revision to incorporate new drugs, revised analytical methods, updated quality specifications, and contemporary regulatory requirements.

➤ *Chronology of Major Editions*

Table 1 Chronology of Major Editions

Period	Major development
1833	East India Company's Dispensary committee recommended publication of a pharmacopoeia.
1844	<i>Bengal Pharmacopoeia and General Conspectus of Medicinal Plants</i> was published.
1940–1945	Drugs and Cosmetics Act, 1940, and Drugs Rules, 1945, established the statutory basis for drug regulation.
1948	Indian Pharmacopoeia Committee was constituted after independence.
1955	First edition of the Indian Pharmacopoeia was published.
1960	Supplement to the first edition was published.
1966	Second edition was published.
1975	Supplement to the second edition was published.
1985	Third edition was published.
1989, 1991	Addenda to the third edition were published.
1996	Fourth edition was published.
2000–2005	Addenda and veterinary-products supplement expanded the IP's scope.
2007	Fifth edition was published.
2010	Sixth edition was published with DVD format.
2014	Seventh edition was published.
2018	Eighth edition was published.
2022	Ninth edition, IP 2022, was published in four volumes.

➤ *Significance of the Evolution*

The historical development of the IP demonstrates a progressive shift from descriptive listings of indigenous remedies to comprehensive, science-based standards for drug identity, purity, strength, and quality. Each edition and supplement has incorporated advances in analytical chemistry, pharmaceutical technology, quality assurance, and regulatory science.

The IP is now an essential component of India's pharmaceutical quality-assurance framework. It supports manufacturers in complying with official standards, assists quality-control laboratories in testing medicines, and provides regulatory authorities with authoritative benchmarks for evaluating drug quality.

III. DISCUSSION

The historical development of the Indian Pharmacopoeia demonstrates the gradual establishment of a national, science-based system for pharmaceutical standardisation in India. Its evolution from early colonial pharmacopoeial initiatives to the present IPC-published compendium reflects the growing need for reproducible standards of drug identity, purity, strength, and quality.

➤ *From Traditional Standards to National Regulation*

The early *Bengal Pharmacopoeia and General Conspectus of Medicinal Plants* of 1844 represented an initial attempt to document locally relevant medicinal substances, but it did not constitute a comprehensive modern quality standard. The later development of the IP was therefore shaped by the need to move beyond descriptive listings and establish testable specifications and analytical procedures.

The Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945, provided the statutory foundation for this transition. Under the Second Schedule of the Act, the IP is recognised as the official book of standards for drugs in India, and its standards are authoritative and legally enforceable.

➤ *Institutional Maturation*

The constitution of the Indian Pharmacopoeia Committee in 1948 and the publication of the first IP edition in 1955 were decisive institutional milestones. They enabled India to develop drug standards suited to national therapeutic needs and indigenous pharmaceutical manufacturing, rather than relying exclusively on foreign pharmacopoeias.

The later creation of the Indian Pharmacopoeia Commission as a dedicated autonomous institution further strengthened this system. The IPC is responsible for revising and publishing the IP and the National Formulary of India,

providing IP Reference Substances, and training stakeholders on pharmacopoeial matters.

Importantly, the IPC's role is standard-setting rather than drug approval. Regulatory decisions concerning drug approval and enforcement remain with the Central Drugs Standard Control Organisation and State Licensing Authorities.

➤ *Scientific and Regulatory Expansion*

Successive editions of the IP show a clear expansion in scientific scope. Early editions primarily addressed conventional chemical drugs and pharmaceutical preparations, whereas later editions incorporated veterinary products, biotechnology-derived therapeutics, vaccines, blood-related products, herbal products, and phytopharmaceutical ingredients.

IP 2022 illustrates this contemporary broadening of scope. It included 92 new monographs, comprising chemical pharmaceuticals, vitamins, minerals, amino acids and fatty acids, biotechnology-derived therapeutic products, human vaccines, blood and blood-related products, herbs and herbal products, and phytopharmaceutical ingredients.

This expansion indicates that the IP has evolved from a largely chemical-pharmaceutical compendium into a broader quality framework capable of addressing complex biological products, traditional and herbal medicines, and emerging therapeutic modalities.

➤ *Role in Quality Assurance*

The IP now functions as a central instrument of pharmaceutical quality assurance in India. Its monographs and general requirements provide manufacturers, quality-control laboratories, and regulators with common benchmarks for testing and assessing medicines.

A drug that fails to conform to applicable IP standards may be considered “not of standard quality,” and its import, manufacture, sale, or distribution can attract action under the Drugs and Cosmetics Act, 1940. This legal enforceability distinguishes the IP from a merely technical reference document and makes it directly relevant to public-health protection.

➤ *Implications of Periodic Revision*

The regular publication of editions, supplements, and addenda is essential because pharmaceutical science, manufacturing technology, and regulatory expectations continue to change. Periodic revision allows the IP to introduce new monographs, update analytical methods, address emerging impurities and quality risks, and accommodate novel product categories.

The movement from print-only editions to digital formats also reflects improved accessibility and usability of pharmacopoeial standards. This supports more efficient implementation by industry, testing laboratories, academic institutions, and regulatory bodies.

➤ *Overall Interpretation*

The IP's history shows a coherent progression: early documentation of medicinal substances, followed by statutory regulation, national standard-setting, institutional consolidation, and contemporary expansion into complex and diverse therapeutic products.

Its present significance lies not only in preserving historical continuity but also in providing an enforceable, regularly updated quality framework. In this sense, the Indian Pharmacopoeia has become both a scientific compendium and a practical regulatory instrument supporting the quality, safety, and efficacy assurance of medicines in India.

IV. CONCLUSION

The Indian Pharmacopoeia has evolved from early efforts to document medicinal substances in colonial India into the country's official, legally enforceable compendium of drug standards. Its development reflects the broader transformation of Indian pharmaceutical practice from traditional and imported references towards a nationally controlled, science-based system of pharmaceutical quality assurance.

The enactment of the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945, established the legislative foundation for drug-quality regulation in India. The subsequent constitution of the Indian Pharmacopoeia Committee in 1948 and publication of the first edition of the IP in 1955 provided the institutional and scientific basis for national pharmacopoeial standardisation.

Successive editions, supplements, and addenda demonstrate the IP's continuous adaptation to advances in pharmaceutical science, analytical technology, and regulatory requirements. The expansion of its scope from conventional chemical medicines to veterinary products, biologicals, vaccines, herbal products, and biotechnology-derived therapeutics illustrates its growing relevance to modern healthcare and pharmaceutical manufacturing.

Under the Second Schedule of the Drugs and Cosmetics Act, 1940, the IP is recognised as the official book of standards for drugs in India. Its standards are authoritative and legally enforceable, and they are used by manufacturers, quality-control laboratories, and regulatory authorities to assess whether medicines meet required quality specifications.[ipc.gov][pib.gov]

The establishment of the Indian Pharmacopoeia Commission as a dedicated autonomous institution has further strengthened the timely revision, publication, and implementation of IP standards. Through its monographs, analytical procedures, reference standards, and training activities, the IPC supports consistent quality evaluation across the Indian pharmaceutical sector.

Overall, the Indian Pharmacopoeia has become a cornerstone of India's pharmaceutical regulatory framework. By providing uniform, scientifically valid, and enforceable

standards, it contributes significantly to the control and assurance of medicine quality, supports public-health protection, and reinforces confidence in domestically manufactured and marketed pharmaceutical products.

REFERENCES

- [1]. Indian Pharmacopoeia Commission. About IP. Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India. Available from: <https://ipc.gov.in/mandates/indian-pharmacopoeia/about-ip.html>
- [2]. Indian Pharmacopoeia Commission. History of Pharmacopoeia in India. IP Online, Indian Pharmacopoeia Commission. Available from: [https://iponline.ipc.gov.in/jspui/indian-pharmacopoeia/history.jsp\[iponline.ipc.gov\]](https://iponline.ipc.gov.in/jspui/indian-pharmacopoeia/history.jsp[iponline.ipc.gov])
- [3]. Indian Pharmacopoeia Commission. About Us. Ministry of Health and Family Welfare, Government of India. Available from: <https://ipc.gov.in/about-us.html>
- [4]. Indian Pharmacopoeia Commission. Formation of IPC. Available from: <https://www.ipc.gov.in/about-us/about-ipc/formation-of-ipc.html>
- [5]. Indian Pharmacopoeia Commission. FAQ: Legal status of the Indian Pharmacopoeia. Available from: <https://ipc.gov.in/faq.html>
- [6]. Indian Pharmacopoeia Commission. Legal Status of Indian Pharmacopoeia. Guidance document GD-01. Available from: https://ipc.gov.in/images/GD-01-Legal_Status_of_IP.pdf
- [7]. Government of India. The Drugs and Cosmetics Act, 1940. Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare. Available from: [https://cdsco.mohfw.gov.in/opencms/resources/UploadCDSCOWeb/2022/acts_and_rules/Drugs%20and%20Cosmetics%20Act,%201940.pdf\[cdsco.mohfw.gov\]](https://cdsco.mohfw.gov.in/opencms/resources/UploadCDSCOWeb/2022/acts_and_rules/Drugs%20and%20Cosmetics%20Act,%201940.pdf[cdsco.mohfw.gov])
- [8]. Government of India. The Drugs Rules, 1945. Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare. Available from: [https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/drug_rules/Drugs%20Rules%201945_2024%2009.09.2024.pdf\[cdsco.gov\]](https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/drug_rules/Drugs%20Rules%201945_2024%2009.09.2024.pdf[cdsco.gov])
- [9]. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2022: Salient features. Available from: <https://www.ipc.gov.in/mandates/indian-pharmacopoeia/indian-pharmacopoeia-2022.html>
- [10]. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2018 and its Addenda. Available from: <https://www.ipc.gov.in/mandates/indian-pharmacopoeia/indian-pharmacopoeia-2018-and-its-addenda.html>
- [11]. Indian Pharmacopoeia Commission. Introduction to the Indian Pharmacopoeia 2018. Available from: https://www.ipc.gov.in/images/Introduction_IP-2018.pdf
- [12]. Press Information Bureau, Government of India. Union Health Minister releases 10th edition of Indian Pharmacopoeia. 20 November 2025. Available from: <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2210754®=3&lang=1>
- [13]. World Health Organization. Index of pharmacopoeias. Working document QAS/11.453/Rev.18. Geneva: World Health Organization; 2025. Available from: https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/current-projects/index-of-pharmacopoeias_may_2025.pdf
- [14]. Kumar S, et al. Ensuring the quality of medicines in India. Journal of Pharmaceutical Policy and Practice. 2023. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10641554/>
- [15]. The Indian Pharmacopoeia Commission. The Indian Pharmacopoeia Commission. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11970485/>